Literature DB >> 18661275

Surgical outcomes of epiretinal membrane removal after successful pars plana vitrectomy for retinal diseases.

Susumu Sakimoto1, Yoshihiro Saito2, Ko Nakata2, Yoshihiro Sakamoto2, Misako Tatebayashi2.   

Abstract

PURPOSE: To evaluate visual outcomes after a removal of an epiretinal membrane (ERM) secondary to rhegmatogenous retinal detachment (RRD), proliferative vitreoretinopathy (PVR), or proliferative diabetic retinopathy (PDR).
METHODS: The medical charts of 51 consecutive patients who underwent PPV to remove an ERM were reviewed in an institutional setting. The preoperative best-corrected visual acuity (BCVA) was evaluated to determine if it was a possible predictor of the postoperative BCVA. The visual outcomes in the RRD, PVR, and PDR groups were compared. Follow-up periods ranged from 13 to 90 months (mean, 40.9 months).
RESULTS: After the ERM was removed, the postoperative BCVA improved significantly by 0.471 logarithm of the minimum angle of resolution units for all groups (t=8.99; P<0.001). The postoperative BCVA improved by two or more lines in 43 eyes (84.3%). Patient age and the preoperative BCVA significantly correlated with the visual improvement (P=0.0082 and P=0.035, respectively).
CONCLUSION: The BCVA improves after removal of an ERM following PPV for eyes with RRD, PVR, or PDR. Patient age and preoperative BCVA correlated with the visual improvement after the ERM removal.

Entities:  

Mesh:

Year:  2008        PMID: 18661275     DOI: 10.1007/s10384-008-0539-5

Source DB:  PubMed          Journal:  Jpn J Ophthalmol        ISSN: 0021-5155            Impact factor:   2.447


  3 in total

1.  Prognostic factors in vitrectomy for epiretinal membranes of the macula.

Authors:  T A Rice; S De Bustros; R G Michels; J T Thompson; S M Debanne; D Y Rowland
Journal:  Ophthalmology       Date:  1986-05       Impact factor: 12.079

2.  Visual outcomes and complications of epiretinal membrane removal secondary to rhegmatogenous retinal detachment.

Authors:  Matthew D Council; Gaurav K Shah; Henry C Lee; Sanjay Sharma
Journal:  Ophthalmology       Date:  2005-07       Impact factor: 12.079

3.  Electron microscopic observation of preretinal membranes.

Authors:  T Yamamoto; H Yamashita; S Hori
Journal:  Jpn J Ophthalmol       Date:  1989       Impact factor: 2.447

  3 in total
  6 in total

1.  Disorganization of Inner Retina and Outer Retinal Morphology in Diabetic Macular Edema.

Authors:  Radha Das; Gareth Spence; Ruth E Hogg; Michael Stevenson; Usha Chakravarthy
Journal:  JAMA Ophthalmol       Date:  2018-02-01       Impact factor: 7.389

2.  Visual outcomes of primary versus secondary epiretinal membrane following vitrectomy and cataract surgery.

Authors:  J Corbin Norton; Mohamed K Soliman; Yit C Yang; Shree Kurup; Ahmed B Sallam
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2021-10-09       Impact factor: 3.117

3.  Visual outcome and prognostic factors after surgery for a secondary epiretinal membrane associated with branch retinal vein occlusion.

Authors:  Hae Min Kang; Hyoung Jun Koh; Sung Chul Lee
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2014-07-20       Impact factor: 3.117

4.  Downregulation of lentivirus-mediated ILK RNAi on tractional force generation in human retinal Müller cells.

Authors:  Yu-ping Zheng; Hui Liu; Hao Zeng; Lei Xiong; Zhao-hui Feng; Nai-xue Sun
Journal:  Acta Pharmacol Sin       Date:  2009-11-16       Impact factor: 6.150

5.  Combined cataract extraction and vitrectomy for macula-sparing retinal detachment: visual outcomes and complications.

Authors:  Kyoung-Nam Kim; Haeng-Jin Lee; Dong-Won Heo; Young-Joon Jo; Jung-Yeul Kim
Journal:  Korean J Ophthalmol       Date:  2015-05-20

6.  Cell-mediated contraction of vitreous explants from chicken embryo: possibility of screening for therapeutic agents against proliferative vitreoretinal diseases.

Authors:  Keitaro Oki; Yoshiki Miyata; Arata Shimada; Terumasa Nagase; Yoshiya Katsura; Hiroshi Kosano
Journal:  Mol Vis       Date:  2013-11-23       Impact factor: 2.367

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.